Novalysin has the ambition to develop safe and efficient antimicrobials against mycobacterial pathogens to overcome the spread of antimicrobial resistance. The focus on mycobacteria is due to the high morbidity and mortality associated with these pathogens. As the antibiotic pipeline has dried out, our purpose is to meet the need for novel measures for treatment that are not only effective but selective and safe without leading to side effects and have low probability of generating resistance.
Menu